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ABSTRACT
BACKGROUND AND PURPOSE: Tentorial dural arteriovenous fistulas are characterized by a high hemorrhagic risk. We evaluated trends
in outcomes and management of tentorial dural arteriovenous fistulas and performed a meta-analysis evaluating clinical and angiographic
outcomes by treatment technique.
MATERIALS AND METHODS: We performed a comprehensive literature search for studies on surgical and endovascular treatment of
tentorial dural arteriovenous fistulas. We compared the proportion of patients undergoing endovascular, surgical, and combined endo-
vascular/surgical management; the proportion of patients presenting with ruptured tentorial dural arteriovenous fistulas; and proportion
of patients with good neurologic outcome across 3 time periods: 1980–1995, 1996–2005, and 2006–2014. We performed a random-effects
meta-analysis, evaluating the rates of occlusion, long-term good neurologic outcome, perioperative morbidity, and resolution of symp-
toms for the 3 treatment modalities.
RESULTS: Twenty-nine studies with 274 patients were included. The proportion of patients treated with surgical treatment alone
decreased from 38.7% to 20.4% between 1980–1995 and 2006–2014. The proportion of patients treated with endovascular therapy alone
increased from 16.1% to 48.0%. The proportion of patients presenting with ruptured tentorial dural arteriovenous fistulas decreased from
64.4% to 43.6%. The rate of good neurologic outcome increased from 80.7% to 92.9%. Complete occlusion rates were highest for patients
receiving multimodality treatment (84.0%; 95% CI, 72.0%–91.0%) and lowest for endovascular treatment (71.0%; 95% CI, 56.0%–83.0%;
P  .01). Long-term good neurologic outcome was highest in the endovascular group (89.0%; 95% CI, 80.0%–95.0%) and lowest for the
surgical group (73.0%; 95% CI, 51.0%–87.0%; P .03).
CONCLUSIONS: Patients with tentorial dural arteriovenous fistulas are increasingly presenting with unruptured lesions, being treated
endovascularly, and experiencing higher rates of good neurologic outcomes. Endovascular treatment was associated with superior
neurologic outcomes but lower occlusion rates.
ABBREVIATIONS: DAVF dural arteriovenous fistula; TDAVF tentorial dural arteriovenous fistula
Intracranial dural arteriovenous fistulas (DAVFs) are abnormaldirect shunts between the dural arteries and dural veins.1 The
shunt is located in the intracranial dura mater with venous drain-
age directed to the dural venous sinuses or cortical veins. Dural
arteriovenous fistulas account for 10%–15% of all intracranial
vascular shunts.1,2 Tentorial dural arteriovenous fistulas
(TDAVFs) constitute only 4% of DAVFs and are characterized by
a high hemorrhagic risk. Because of this, these lesions are treated
aggressively on diagnosis.3-5
Traditionally, surgical resection was the only treatment avail-
able for these lesions. However, endovascular embolization, ei-
ther alone or in combination with surgery, is increasingly used.6
Stereotactic radiosurgery is also increasingly used as an adjunct to
surgical and endovascular treatment.7We performed a systematic
review of the literature on surgical and endovascular treatment of
TDAVFs from 1980 to 2014. The purpose of our study was the
following: 1) to determine whether there was a shift from primar-
ily surgical treatments to endovascular and multimodality treat-
ment during this time period, 2) to determine whether the pro-
portion of patients presenting with ruptured TDAVFs during this
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time period has changed, 3) to determinewhether the rate of good
neurologic outcome has changed, and 4) to evaluate clinical and
angiographic outcomes in endovascular, surgical, and combined
treatments by performing a random-effects meta-analysis.
MATERIALS AND METHODS
A comprehensive literature search of the data bases (PubMed,
Ovid MEDLINE, and Ovid EMBASE) was designed and con-
ducted by an experienced librarian with input from the au-
thors. The key words “endovascular,” “catheterization,” “per-
cutaneous,” “embolization,” “coil,” “cerebral veins,”
“intracranial,” “arteriovenous fistula,” “surgery,” “DAVF,”
“resection,” and “tentorial” were used in both “AND” and
“OR” combinations. The search was limited to articles pub-
lished from 1980 to June 2014 in the English language only. All
studies reporting patients treated with surgery or endovascular
therapy for TDAVFs were selected. Inclusion criteria were the
following: 1) series of5 patients, with available data on clin-
ical and/or angiographic outcomes. Studies with fewer than 5
patients were included only if they were published before 1995.
Two reviewers selected the included studies. For each study, we
extracted the following information: patient presentation
(ruptured or unruptured), treatment technique (endovascu-
lar, surgical, or combined), long-term good neurologic out-
come, long-term neurologic morbidity, angiographic occlu-
sion status at last follow-up, resolution of symptoms for
unruptured TDAVFs, and year of publication. Good neuro-
logic outcome was defined as a modified Rankin Scale score of
2. In cases in which a modified Rankin Scale score was not
available, good neurologic outcome was determined if the
study used terms such as “no morbidity” or “good recovery.”
The primary objective of this study was to determine the
clinical and angiographic outcomes of patients with endovas-
cular, surgical, or multimodality treatment. The secondary ob-
jective was to determine trends in patient presentations, treat-
ment type, and clinical outcome following treatment of
TDAVFs. For this secondary objective, studies were divided
into 3 periods: 1) studies published from 1995 and earlier, 2)
studies published from 1996 to 2005, and 3) studies published
from 2006 to 2014. For this secondary objective, we performed
the following analyses: 1) the proportion of patients presenting
with ruptured TDAVFs in each period; 2) the proportion of
patients receiving endovascular, surgical, and combined treat-
ments; and 3) the proportion of patients with good neurologic
outcome.
Study Quality
We modified the Newcastle-Ottawa Quality Assessment Scale
for case-control studies to assess the quality of the studies in-
cluded in this meta-analysis. The Newcastle-Ottawa score is
designed for use in case-control-type studies; however, be-
cause none of the studies included in our analysis were of this
type, we assessed study quality on the basis of the following: 1)
The study included all patients or consecutive patients versus a
selected sample, 2) the angiographic and clinical follow-up was
satisfactory, thus allowing ascertainment of all outcomes, 3)
the case definition was adequate (ie, the location and presen-
tation of the DAVF were clearly stated), 4) outcomes were
clearly reported, and 5) the interventionalists/surgeons treat-
ing the patients were the same as those who assessed angio-
graphic and clinical outcomes. High-quality studies were de-
fined as those with 20 patients, high rates of clinical
follow-up with clearly reported outcomes, and independent
assessment of angiographic and clinical outcomes.
Statistical Analysis
All included studies were noncomparative. We estimated from
each cohort the cumulative incidence (event rate) and 95%
confidence interval for each outcome. Event rates for each in-
tervention were pooled in a meta-analysis across studies by
using the random-effects model.8 Anticipating heterogeneity
between studies, we chose this model a priori because it incor-
porates within-study and between-study variances. We also
extracted a 2 2 table for each studied outcome for interaction
testing and calculated P values for the comparisons between
endovascular and surgical groups, surgical and multimodality
groups, and endovascular and multimodality groups. Hetero-
geneity of treatment effect across studies was evaluated by us-
ing the I2 statistic.9
RESULTS
Literature Review
Studies included in our review are summarized in Table 1. Our
literature search yielded 986 articles; 879 articles were excluded
after reading the abstract alone, with a total of 107 articles re-
viewed. Of these, 78 were excluded for either not including
TDAVFs in their patient population or not reporting patient pre-
sentation or angiographic outcomes. In total, 29 studies with 274
patientsmet our inclusion criteria. The search results are summa-
rized in Fig 1.
Meta-Analysis Outcomes: All Patients
Meta-analysis outcomes are summarized in Table 2. Forest plots are
provided as On-line Figs 1–5. The rates of complete occlusion at last
follow-up were 71.0% (95% CI, 56.0%–83.0%) for the endovascu-
lar-only group, 81.0% (95%CI, 61.0%–92.0%) for the surgery-only
group, and 84.0% (95% CI, 72.0%–91.0%) for the combined-treat-
ment group. The combined-treatment group had a statistically sig-
nificantly higher rate of complete occlusion (P  .01). The rate of
long-term neurologic morbidity was 5.0% (95% CI, 2.0%–11.0%)
for the endovascular group, 8.0% (95% CI, 2.0%–21.0%) for the
surgery-only group, and 6.0% (95% CI, 2.0%–15.0%) for the com-
bined-treatment group. There was no difference between groups in
the ratesof long-termneurologicmorbidity.Perioperativemorbidity
occurred in 6.0% (95% CI, 3.0%–13.0%) for the endovascular
group, 18.0% (95% CI, 8.0%–35.0%) for the surgery-only group,
and 14.0% (95% CI, 8.0%–24.0%) for the combined-treatment
group. Patients treated with endovascular therapy had signifi-
cantly lower perioperative morbidity rates than those treated
with surgery (P  .03) and combined treatments (P  .01).
The long-term good neurologic outcome rates were 89.0%
(95% CI, 80.0%–95.0%) for the endovascular group, 73.0%
(95% CI, 51.0%–87.0% for the surgical group, and 87.0%
(95% CI, 71.0%–94.0%) for the combined-treatment group.
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Long-term good neurologic outcome rates were significantly
higher in the endovascular group than in the surgery group
(P  .03).
Meta-Analysis Outcomes: Patients with Unruptured TDAVFs
Meta-analysis outcomes are summarized in Table 2. Forest plots are
provided as On-line Figs 1–5. The rates of complete occlusion at last
follow-up were 76.0% (95% CI, 54.0%–
89.0%) for the endovascular-only group,
89.0% (95% CI, 69.0%–97.0%) for the
surgery-only group, and 78.0% (95% CI,
53.0%–92.0%) for the combined-treat-
ment group. The rates of long-term neu-
rologic morbidity were 10.0% (95% CI,
3.0%–27.0%) for the endovascular group,
11.0% (95%CI, 3.0%–31.0%) for the sur-
gery-only group, and 10.0% (95% CI,
3.0%–28.0%) for the combined-treat-
ment group. Perioperative morbidity oc-
curred in 10.0% (95% CI, 3.0%–27.0%)
for the endovascular group, 18.0% (95%
CI, 5.0%–48.0%) for the surgery-only
group, and 21.0%(95%CI, 8.0%–46.0%)
for the combined-treatment group. The
rates of resolution of symptoms were
82.0%(95%CI, 59.0%–94.0%) for the en-
dovascular group, 50.0% (95% CI,
18.0%–82.0%) for the surgery-only
group, and 73.0% (95% CI, 37.0%–
92.0%) for the combined-treatment
group. There were significantly higher
rates of symptom resolution in the endovascular group com-
pared with the surgical group (P  .03). The long-term good
neurologic outcome rates were 95.0% (95% CI, 91.1%–99.0%)
for the endovascular group, 56.0% (95% CI, 20.0%–86.0%)
for the surgical group, and 88.0% (95% CI, 68.0%–96.0%) for
the combined-treatment group, with significantly better out-
comes in the endovascular compared with surgical group (P
FIG 1. Literature search flow chart.
Table 1: Study characteristics
Authors, Year Treatment Type Clinical/Angiographic Follow-Up (mo) Rupture Status No. of Patients Risk of Bias
Abud et al, 201119 SE 6 NA 5 Medium
Bret et al, 199420 S 3 U 1 High
Byrne and Garcia, 20133 SE NA RU 13 Medium
Fardoun et al, 198121 S 12 R 1 High
Grisoli et al, 198422 S 10 RU 4 High
Gross and Du, 201323 S 25 RU 15 Medium
Hatano et al, 201324 S 6 U 9 Medium
Huang et al, 200925 E 13 RU 14 Medium
Ito et al, 199526 S 11 R 1 High
Kakarla et al, 200727 SC 21.2 RU 21 Medium
Lawton et al, 200828 C 50 RU 31 Medium
Lewis et al, 199429 S 12 RU 6 Medium
Lewis et al, 199730 E 30 RU 9 Medium
Liu et al, 201431 E 33 U 26 Medium
Lucas Cde et al, 200532 SEC 3 NA 20 Medium
Lucas et al, 199733 EC NA U 1 High
Natarajan et al, 201034 EC 16.5 R 7 Medium
Ott et al, 199335 E 16 U 1 High
Pandey et al, 201136 S NA NA 6 High
Pierot et al, 199237 SEC 1 U 6 High
Piippo et al, 201338 SEC NA NA 7 High
Puffer et al, 201216 C 4.6 RU 9 Medium
Rabinov et al, 201339 E NA NA 5 Medium
Tomak et al, 200340 SEC 60 RU 22 Medium
van Lindert et al, 200041 C 30 RU 5 Medium
van Rooij et al, 200642 E 3 RU 6 Medium
Wachter et al, 201143 SE NA NA 9 Medium
Wajnberg et al, 201244 E 15.5 RU 9 Medium
Zhou et al, 20076 SC 30 RU 5 Medium
Note:—S indicates surgery; E, endovascular; C, combined; R, ruptured; U, unruptured; NA, not available.
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.01) and the combined-treatment compared with the surgical
group (P  .01).
Meta-Analysis Outcomes: Patients with Ruptured TDAVFs
Meta-analysis outcomes are summarized in Table 2. Forest
plots are provided as On-line Figs 1–5. The rates of complete
occlusion at last follow-up were 78.0% (95% CI, 61.0%–
88.0%) for the endovascular-only group, 88.0% (95% CI,
63.0%–97.0%) for the surgery-only group, and 82.0% (95%
CI, 62.0%–93.0%) for the combined-treatment group. The
rates of long-term neurologic morbidity were 7.0% (95%
CI, 3.0%–19.0%) for the endovascular group, 12.0% (95% CI,
3.0%–37.0%) for the surgery-only group, and 9.0% (95% CI,
3.0%–28.0%) for the combined-treatment group. Periopera-
tive morbidity occurred in 7.0% (95%CI, 3.0%–19.0%) for the
endovascular group, 20.0% (95% CI, 6.0%–49.0%) for the
surgery-only group, and 21.0% (95% CI, 10.0%–38.0%) for
the combined-treatment group. The long-term good neuro-
logic outcome rates were 87.0% (95% CI, 71.0%–94.0%) for
the endovascular group, 73.0% (95%CI, 44.0%–90.0%) for the
surgical group, and 88.0% (95% CI, 71.0%–94.0%) for the
combined-treatment group. There were no significant differ-
ences among groups for any of the outcomes.
Secondary Outcomes
The proportion of patients treated with surgical treatment alone
decreased from 38.7% to 20.4% between 1980–1995 and 2006–
2014. The proportion of patients treated with endovascular ther-
apy alone increased from 16.1% to 48.0% (Fig 2). The proportion
of patients presenting with ruptured TDAVFs decreased from
64.4% to 43.6% (Fig 3). The rate of good neurologic outcome
increased from 80.7% to 92.9% (Fig 4).
DISCUSSION
The results of this study confirm that contemporary treatment of
TDAVF leads to a high percentage of both angiographic cure and
favorable clinical outcomes. Successful treatment is achieved uni-
formly among ruptured and unruptured lesions, with comparable
low morbidity, among endovascular, surgical, and combined-treat-
ment modalities. Endovascular and multimodality approaches ap-
pear to be associated with a higher rate of symptom resolution in
patients with nonhemorrhagic presentation, compared with stand-
alone surgical approaches. Furthermore, our study reveals a sus-
tained shift from surgery toward an endovascular approach as the
preferred treatment technique of TDAVF in the past 2 decades. Ad-
vances in the understanding of the pathologic anatomy of TDAVFs
coupledwith significant improvement inmicrocatheter and embolic
material technology andmicrosurgical technique are reflected in the
achievement of improved neurologic outcomes in this period. Fi-
nally, an increasing number of TDAVFs are now diagnosed and
treated before they present with hemorrhage, presumably due to
wide availability and improved resolution of noninvasive angiogra-
phy and the recognition of venous hypertension as a prominent
cause of neurologic morbidity.
Dural arteriovenous fistulas of the tentorium have been tradi-
tionally considered among the most likely to present with hemor-
rhageoraggressivenonhemorrhagicneurologicdysfunction. In their
review of 337 DAVF cases in 1990, Awad et al10 found that 97% of
TDAVFs presented with either hemorrhage or symptomatic venous
hypertension. In fact, the overwhelming majority of patients with
DAVFs who present with hemorrhage have TDAVFs.5 It is now rec-
ognized that thepresenceof retrograde leptomeningeal drainage,not
DAVF location, is themajor determining factor of themode of clin-
ical presentation, and TDAVFs are universally associated with retro-
grade leptomeningeal drainage.11 The natural history of symptom-
Table 2: Outcomes of random-effects meta-analysis
Endovascular I2 Surgical I2 Multimodality I2
P Value
E vs S
P Value
E vs M
P Value
S vs M
Ruptured and unruptured
Complete occlusion 71.0 (56.0–83.0) 43 81.0 (61.0–92.0) 33 84.0 (72.0–91.0) 14 .09 .01 .63
Long-term neurologic
morbidity
5.0 (2.0–11.0) 0 8.0 (2.0–21.0) 0 6.0 (2.0–15.0) 0 .66 1.00 1.00
Perioperative morbidity 6.0 (3.0–13.0) 0 18.0 (8.0–35.0) 0 14.0 (8.0–24.0) 0 .03 .01 .76
Good long-term neurologic
outcome
89.0 (80.0–95.0) 0 73.0 (51.0–87.0) 21 87.0 (71.0–94.0) 0 .03 1.00 .07
Unruptured
Complete occlusion 76.0 (54.0–89.0) 0 89.0 (69.0–97.0) 50 78.0 (53.0–92.0) 9 .48 .95 .51
Long-term neurologic
morbidity
10.0 (3.0–27.0) 0 11.0 (3.0–31.0) 0 10.0 (3.0–28.0) 0 .97 1.00 .95
Perioperative morbidity 10.0 (3.0–27.0) 0 18.0 (5.0–48.0) 0 21.0 (8.0–46.0) 0 .25 .45 .70
Good long-term neurologic
outcome
95.0 (91.0–99.0) 55 56.0 (20.0–86.0) 0 87.0 (66.0–96.0) 0 .01 .72 .01
Resolution of symptoms
(unruptured only)
82.0 (59.0–94.0) 0 50.0 (18.0–82.0) 48 73.0 (37.0–92.0) 0 .03 .57 .42
Ruptured
Complete occlusion 78.0 (61.0–88.0) 0 88.0 (63.0–97.0) 0 82.0 (62.0–93.0) 0 .51 .65 .63
Long-term neurologic
morbidity
7.0 (3.0–19.0) 0 12.0 (3.0–37.0) 0 9.0 (3.0–28.0) 0 .95 .93 .91
Perioperative morbidity 7.0 (3.0–19.0) 0 20.0 (6.0–49.0) 0 21.0 (10.0–38.0) 0 .14 .02 .76
Good long-term neurologic
outcome
87.0 (71.0–94.0) 0 73.0 (44.0–90.0) 0 88.0 (68.0–96.0) 0 .44 .84 .22
Note:—M indicates multimodality; S, surgery; E, endovascular.
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atic DAVF with retrograde leptomeningeal drainage is particularly
unfavorable. In 1 study of 20 patients who received either no or par-
tial treatment for DAVFs with retrograde leptomeningeal drainage,
the annualmortality ratewas calculated at 10.4%and the annual risk
for hemorrhage or nonhemorrhagic neurologic deficits after the first
presentation were 8.1% and 6.9%, respectively. Five patients in this
series hadDAVFs of the tentorium, of whom3 died and 1 hadmod-
erate disability on follow-up.12 On the other hand, recent studies
have shown that asymptomaticDAVFswith retrograde leptomenin-
geal drainage may have a relatively benign natural course. Careful
inspection reveals that thismay not necessarily be valid in the case of
TDAVFs, as evidenced in a series of 17 asymptomatic patients, in
which only 1 patient had a DAVF of the tentorium and who, in fact,
presented with subarachnoid hemorrhage after partial treatment.13
FIG 2. Treatment technique type by time period. E indicates endovascular; S, surgical; M, combined.
FIG 3. Rate of good neurologic outcome by time period.
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Until recently, DAVFs of the tentorium were considered can-
didates only for surgical interruption in the form ofmicrosurgical
disconnection of the proximal leptomeningeal venous drainage.14
The introduction of ethylene-vinyl alcohol (Onyx; Covidien, Ir-
vine, California), a permanent, nonadhesive, liquid embolic
agent, has revolutionizedDAVF treatment andmay be the leading
cause of the shift toward a predominantly endovascular treatment
paradigm in TDAVFs. In transarterial DAVFOnyx embolization,
a proximal plug is created around the distal tip of the microcath-
eter to produce sufficient proximal flow arrest and allow distal
penetration of ethylene-vinyl alcohol into the proximal venous
outlet while allowing retrograde occlusion of contributing arterial
feeders. More recently, dual-lumen balloon microcatheters are
used that allow the unopposed forward penetration of Onyx,
without the time-consuming effort of plug formation, while con-
currently decreasing the risk of premature proximal reflux.15 The
posterior branch of the middle meningeal artery almost always
provides arterial supply to a TDAVF and provides a natural direct
access to the venous collector system of the fistula. Furthermore,
the middle meningeal artery and its branches run a relatively straight
course and are anchored on the dura, making failed microcatheter re-
trieval rare despite substantial Onyx reflux. Although proximal Onyx
refluxmay occur with a highmargin of safety in themiddlemeningeal
artery, reflux shouldnot be allowed inproximity to the level of the fora-
menspinosumtoavoidinadvertentcompromiseofthearterialsupplyto
the trigeminal and facial nerves.16
Even thoughwe have attempted to summarize data on all pub-
lished series of treated TDAVFs, our study has certain limitations.
The results of separate case series were published by multiple au-
thors who reported independently assessed data and who deter-
mined different specific variables that are included in this article.
However, the extracted data have been derived from a fairly ho-
mogeneous and strictly defined patient population. Furthermore,
our study has publication bias, because patients who had either
uneventful or poor outcomes may have been excluded from pub-
lished results. Moreover, treatmentmodalities have varied during
the time course of the published series; this variation makes
standardization of treatment paradigms difficult. Last, uniform
assessment and reporting of complications in a standardized fash-
ion were lacking. On the basis of the Grading of Recommenda-
tions, Assessment, Development and Evaluation framework, the
quality of evidence (confidence in estimates) is very low because
of imprecision, heterogeneity, and methodologic limitations of
the included studies.17,18 Nevertheless, this meta-analysis provides
usefuldata to sharewithpatients and familieswhenassessing the risksof
treatmentofTDAVFsandrepresents abenchmarkagainstwhich future
studiescanbecompared.Withanalysisof270patients, this iscurrently
thelargeststudyexaminingoutcomesofsurgicalandendovasculartreat-
ment of TDAVFs, to our knowledge.
CONCLUSIONS
During the past 35 years, patients with TDAVFs have been in-
creasingly presentingwith unruptured lesions, receiving endovas-
cular treatment, and experiencing higher rates of good neurologic
outcomes. Endovascular treatment was associated with the best
long-term neurologic outcomes but lower occlusion rates. Com-
bined endovascular and surgical treatment was associated with
high occlusion rates and low morbidity. Increasing use of Onyx
may continue to shift the balancemore andmore toward increas-
ing endovascular treatment as the sole mode of therapy.
Disclosures: Giuseppe Lanzino—UNRELATED:Consultancy: Covidien/ev3.* *Money
paid to the institution.
FIG 4. Proportion of patients presenting with ruptured TDAVFs by time period.
1910 Cannizzaro Oct 2015 www.ajnr.org
REFERENCES
1. Hiramatsu M, Sugiu K, Hishikawa T, et al. Epidemiology of dural
arteriovenous fistula in Japan: analysis of Japanese Registry of
Neuroendovascular Therapy (JR-NET2). Neurol Med Chir (To-
kyo) 2014;54:63–71
2. So¨derman M, Pavic L, Edner G, et al. Natural history of dural arte-
riovenous shunts. Stroke 2008;39:1735–39
3. Byrne JV, Garcia M. Tentorial dural fistulas: endovascular manage-
mentanddescriptionof themedialdural-tentorialbranchof thesupe-
rior cerebellar artery.AJNRAm JNeuroradiol 2013;34:1798–804
4. Cha KC, Yeon JY, Kim GH, et al. Clinical and angiographic results
of patients with dural arteriovenous fistula. J Clin Neurosci
2013;20:536–42
5. Daniels DJ, Vellimana AK, Zipfel GJ, et al. Intracranial hemorrhage
from dural arteriovenous fistulas: clinical features and outcome.
Neurosurg Focus 2013;34:E15
6. Zhou LF, Chen L, Song DL, et al. Tentorial dural arteriovenous fis-
tulas. Surg Neurol 2007;67:472–81; discussion 481–82
7. Yang HC, Kano H, Kondziolka D, et al. Stereotactic radiosurgery
with or without embolization for intracranial dural arteriovenous
fistulas. Neurosurgery 2010;67:1276–83; discussion 1284–85
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control
Clin Trials 1986;7:177–88
9. Higgins JP, Thompson SG, Deeks JJ, et al.Measuring inconsistency
in meta-analyses. BMJ 2003;327:557–60
10. Awad IA, Little JR, Akarawi WP, et al. Intracranial dural arterio-
venous malformations: factors predisposing to an aggressive neu-
rological course. J Neurosurg 1990;72:839–50
11. Davies MA, TerBrugge K, Willinsky R, et al. The validity of classifi-
cation for the clinical presentation of intracranial dural arterio-
venous fistulas. J Neurosurg 1996;85:830–37
12. van Dijk JM, terBrugge KG, Willinsky RA, et al. Clinical course of
cranial dural arteriovenous fistulas with long-term persistent cor-
tical venous reflux. Stroke 2002;33:1233–36
13. Strom RG, Botros JA, Refai D, et al. Cranial dural arteriovenous
fistulae: asymptomatic cortical venous drainage portends less ag-
gressive clinical course.Neurosurgery 2009;64:241–47
14. Thompson BG, Doppman JL, Oldfield EH. Treatment of cranial du-
ral arteriovenous fistulae by interruption of leptomeningeal ve-
nous drainage. J Neurosurg 1994;80:617–23
15. Rammos S, Bortolotti C, Lanzino G. Endovascular management of
intracranial dural arteriovenous fistulae. Neurosurg Clin N Am
2014;25:539–49
16. PufferRC,DanielsDJ,KallmesDF, et al.CurativeOnyxembolizationof
tentorial dural arteriovenous fistulas.Neurosurg Focus 2012;32:E4
17. BalshemH,HelfandM, Schu¨nemannHJ, et al.GRADE guidelines: 3.
Rating the quality of evidence. J Clin Epidemiol 2011;64:401–06
18. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the
quality of evidence—imprecision. JClinEpidemiol2011;64:1283–93
19. Abud TG, Nguyen A, Saint-Maurice JP, et al. The use of Onyx in
different types of intracranial dural arteriovenous fistula. AJNR
Am J Neuroradiol 2011;32:2185–91
20. Bret P, Salzmann M, Bascoulergue Y, et al. Dural arteriovenous fis-
tula of the posterior fossa draining into the spinalmedullary veins:
an unusual cause of myelopathy—case report. Neurosurgery 1994;
35:965–68; discussion 968–99
21. Fardoun R, Adam Y, Mercier P, et al. Tentorial arteriovenous mal-
formation presenting as an intracerebral hematoma: case report.
J Neurosurg 1981;55:976–78
22. Grisoli F, Vincentelli F, Fuchs S, et al. Surgical treatment of tentorial
arteriovenous malformations draining into the subarachnoid
space: report of four cases. J Neurosurg 1984;60:1059–66
23. Gross BA, Du R. Surgical treatment of high grade dural arterio-
venous fistulae. J Clin Neurosci 2013;20:1527–32
24. Hatano T, Bozinov O, Burkhardt JK, et al. Surgical treatment of
tentorial dural arteriovenous fistulae located around the tentorial
incisura. Neurosurg Rev 2013;36:429–35
25. Huang Q, Xu Y, Hong B, et al. Use of Onyx in the management of
tentorial dural arteriovenous fistulae. Neurosurgery 2009;65:287–
92; discussion 292–93
26. ItoM, Sonokawa T,MishinaH, et al.Reversible dural arteriovenous
malformation-induced venous ischemia as a cause of dementia:
treatment by surgical occlusion of draining dural sinus—case re-
port. Neurosurgery 1995;37:1187–91; discussion 1191–92
27. Kakarla UK, Deshmukh VR, Zabramski JM, et al. Surgical treatment
of high-risk intracranial dural arteriovenous fistulae: clinical out-
comes and avoidance of complications. Neurosurgery 2007;61:447–
57; discussion 457–59
28. LawtonMT, Sanchez-Mejia RO, PhamD, et al. Tentorial dural arte-
riovenous fistulae: operative strategies and microsurgical results
for six types. Neurosurgery 2008;62(3 suppl 1):110–24
29. LewisAI,TomsickTA,TewJM, Jr.Managementof tentorialdural arterio-
venousmalformations:transarterialembolizationcombinedwithstereo-
tactic radiationor surgery. JNeurosurg1994;81:851–59
30. Lewis AI, Rosenblatt SS, Tew JM Jr. Surgical management of deep-
seated dural arteriovenous malformations. J Neurosurg 1997;87:
198–206
31. Liu C, Xu B, Song D, et al. Clinical approach of using Onyx via
transarterial access in treating tentorial dural arteriovenous fistula.
Neurol Res 2014;36:983–91
32. Lucas Cde P, PrandiniMN, Caldas JG.Analysis of the best therapeu-
tic alternative for intracranial dural arteriovenous malformations.
Arq Neuropsiquiatr 2005;63:605–13
33. Lucas CP, Zabramski JM, Spetzler RF, et al. Treatment for intracra-
nial dural arteriovenous malformations: a meta-analysis from the
English language literature. Neurosurgery 1997;40:1119–30; discus-
sion 1130–32
34. Natarajan SK, Ghodke B, Kim LJ, et al.Multimodality treatment of
intracranial dural arteriovenous fistulas in the Onyx era: a single
center experience.World Neurosurg 2010;73:365–79
35. Ott D, Bien S, Krasznai L. Embolization of a tentorial dural arterio-
venous fistula presenting as atypical trigeminal neuralgia. Head-
ache 1993;33:503–08
36. Pandey P, SteinbergGK,Westbroek EM, et al. Intraoperative angiog-
raphy for cranial dural arteriovenous fistula. AJNR Am J Neurora-
diol 2011;32:1091–95
37. Pierot L, Chiras J,Meder JF, et al.Dural arteriovenous-fistulas of the
posterior fossa draining into subarachnoid veins. AJNR Am J Neu-
roradiol 1992;13:315–23
38. Piippo A, Niemela M, van Popta J, et al. Characteristics and long-
term outcome of 251 patients with dural arteriovenous fistulas in a
defined population. J Neurosurg 2013;118:923–34
39. Rabinov JD, Yoo AJ, Ogilvy CS, et al. ONYX versus n-BCA for em-
bolization of cranial dural arteriovenous fistulas. J Neurointerv Surg
2013;5:306–10
40. Tomak PR, Cloft HJ, Kaga A, et al. Evolution of the management of
tentorial dural arteriovenous malformations. Neurosurgery 2003;
52:750–60; discussion 760–62
41. van Lindert E, Hassler W, Ku¨hne D, et al. Combined endovascular-
microsurgical treatment of tentorial-incisural dural arteriovenous
malformations: report of five cases. Minim Invasive Neurosurg
2000;43:138–43
42. van Rooij WJ, Sluzewski M, Beute GN. Tentorial artery emboliza-
tion in tentorial dural arteriovenous fistulas. Neuroradiology
2006;48:737–43
43. Wachter D, Hans F, Psychogios MN, et al. Microsurgery can cure
most intracranial dural arteriovenous fistulae of the sinus andnon-
sinus type. Neurosurg Rev 2011;34:337–45; discussion 345
44. Wajnberg E, Spilberg G, RezendeMT, et al. Endovascular treatment
of tentorial dural arteriovenous fistulae. IntervNeuroradiol 2012;18:
60–68
AJNR Am J Neuroradiol 36:1905–11 Oct 2015 www.ajnr.org 1911
